As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against its competitors. | As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ...

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its ...

which allows drugmakers to get their generic medicines approved for one or several—but not all—approved indications of their brand-name counterparts. Novartis disagrees with the decision and ...

Swiss pharmaceutical giant Novartis raised its 2024 financial targets Tuesday after posting rising sales and margins in the third quarter, thanks in part to increased production of a prostate cancer ...

Swiss drug major Novartis AG on Tuesday raised its core operating income and sales guidance for fiscal 2024 after reporting ...

With their headquarters in next year’s Host City, it’s great to have Novartis, a global leader in healthcare, supporting the ...

In its upcoming report, Novartis (NVS) is predicted by Wall Street analysts to post quarterly earnings of $1.94 per share, reflecting an increase of 11.5% compared to the same period last year.

Novartis CEO Vas Narasimhan talks to CNBC about the company's latest results and the potential impact of the U.S. election on the business.

California VC firm Aditum Bio is reaching across the Pacific to hatch a brand-new biotech. Teaming up with China ... Jimenez ...

During the trial, patients treated with Fabhalta experienced a significant reduction in proteinuria as early as two weeks.

Swiss drug major, on Tuesday revised up its annual sales guidance after it reported a surge in net profit for the ...

The European Broadcasting Union (EBU) is delighted to announce Novartis as an ‘Official Partner’ for the 69th Eurovision Song Contest when it’s hosted in their hometown in Basel, Switzerland, next May ...